Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiawei Peony-Glycyrrhiza Decoction is a traditional Chinese herbal medicine, also known as Peony-Glycyrrhiza Decoction (PGD), Shaoyao-Gancao-Tang, or Shakuyaku Kanzo-To. It is composed primarily of the roots of Paeonia (peony) and Glycyrrhiza (licorice) and contains active compounds such as albiflorin, paeoniflorin, benzoylpaeoniflorin, liquiritin, and glycyrrhetinic acid. This multi-component herbal formulation is being investigated for the treatment of antipsychotic-induced hyperprolactinemia, a common side effect of certain antipsychotic medications. Its therapeutic effects are believed to stem from its ability to modulate the dopaminergic system, specifically by enhancing dopamine D2 receptor and dopamine transporter expression, and by suppressing prolactin secretion and synthesis, as well as restoring serum progesterone levels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jiawei Peony-Glycyrrhiza Decoction.